Sanofi | SNY

Stock Price
46.50
Daily Change
1.18 2.60%
Monthly
0.69%
Yearly
-19.47%
Q3 Forecast
46.16

Peers Price Chg Day Year Date
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Corcept Therapeutics 69.36 -0.01 -0.01% 101.75% Sep/05
Genmab 1,751.50 6.50 0.37% -5.83% Sep/05
Galapagos 28.44 1.84 6.92% 11.53% Sep/06
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Glaxosmithkline 40.50 0.89 2.25% -7.26% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Novartis 129.82 1.34 1.04% 11.22% Sep/05
Prestige Brands 65.05 -1.70 -2.55% -12.50% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Perrigo 23.49 -0.25 -1.05% -19.14% Sep/02
Drreddys Laboratories 14.34 0.19 1.34% -81.89% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sanofi 46.50 1.18 2.60% -19.47% Sep/05
Supernus Pharmaceuticals 46.00 0.57 1.25% 35.93% Sep/05
UCB 206.90 2.30 1.12% 28.99% Sep/05
Canopy Growth 2.02 0.11 5.76% -66.72% Sep/05
Zoetis 153.32 0.12 0.08% -19.13% Sep/05


Sanofi traded at $46.50 this Friday September 5th, increasing $1.18 or 2.60 percent since the previous trading session. Looking back, over the last four weeks, Sanofi gained 0.69 percent. Over the last 12 months, its price fell by 19.47 percent. Looking ahead, we forecast Sanofi to be priced at 46.16 by the end of this quarter and at 45.16 in one year, according to Trading Economics global macro models projections and analysts expectations.

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.